AXGN

SEC source: 0000805928-25-000125 · wk-form4_1761336538.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100

F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.045 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000805928-25-000122 · wk-form4_1759871884.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,557

F1 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.01 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 4

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,293

F4 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.60 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 3

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Trust

Disclosed balance after: 0

F3 · price: The sale is from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee.

F4 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.60 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 2

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,864

F2 · price: The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.02 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000805928-25-000119 · wk-form4_1759784056.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Trust

Disclosed balance after: 7,600

F1 · price: The sale from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee, reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.04 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000805928-25-000116 · wk-form4_1758057719.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,649

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on September 13, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0000805928-25-000116 · wk-form4_1758057719.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,786

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

SEC source: 0000805928-25-000102 · wk-form4_1750450260.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000101 · wk-form4_1750450217.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000100 · wk-form4_1750450184.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000099 · wk-form4_1750450149.xml · derivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000098 · wk-form4_1750450115.xml · derivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000097 · wk-form4_1750450070.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000096 · wk-form4_1750450032.xml · derivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,867

Underlying: Common Stock · 18,867 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · derivative · entry 5

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,248

Underlying: Common Stock · 4,000 shares

Expires 2034-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options vested on the first anniversary of the grant date, which was June 6, 2024.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · derivative · entry 4

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,586 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options vested on the first anniversary of the grant date, which was September 1, 2023.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · nonDerivative · entry 3

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 10, 2025 in multiple transactions at prices ranging from $10.69 to $10.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · nonDerivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000086 · wk-form4_1749673656.xml · nonDerivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,580

F1 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-25-000084 · wk-form4_1749673557.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,826

F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-25-000085 · wk-form4_1749673609.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,743

F1 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-25-000083 · wk-form4_1749673506.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,484

F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-25-000082 · wk-form4_1749673449.xml · nonDerivative · entry 1

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,743

F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-25-000081 · wk-form4_1749673393.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,943

F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025, in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · derivative · entry 4

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,586

Underlying: Common Stock · 12,850 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options vested on the first anniversary of the grant date, which was September 1, 2023.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · nonDerivative · entry 3

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,345

F2 · price: The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $11.15 to $11.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · nonDerivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,557

F1 · price: The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $11.15 to $11.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000070 · wk-form4_1748031148.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,557

SEC source: 0000805928-25-000066 · wk-form4_1747435228.xml · derivative · entry 1

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on May 12, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on May 12, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on May 12, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on May 12, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000050 · wk-form4_1743022429.xml · derivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000048 · wk-form4_1743022368.xml · derivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000046 · wk-form4_1743022084.xml · derivative · entry 1

DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,300

Underlying: Common Stock · 176,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000044 · wk-form4_1743022024.xml · derivative · entry 1

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 4

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,762

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 16, 2025. This sale does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 19, 2025 in multiple transactions at $17.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · derivative · entry 7

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,150

Underlying: Common Stock · 23,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F7 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F7 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · derivative · entry 6

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,363

Underlying: Common Stock · 6,362 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · derivative · entry 5

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,950 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2025.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2025.

SEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,361

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2025.

SEC source: 0000805928-25-000028 · wk-form4_1741134151.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,005

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 28, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 4, 2025 in multiple transactions at prices ranging from $18.34 to $18.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000037 · wk-form4_1741218547.xml · nonDerivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,683

F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 1, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 4, 2025 in multiple transactions at prices ranging from $18.34 to $18.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000035 · wk-form4_1741217056.xml · nonDerivative · entry 2

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,285

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 1, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 4, 2025 in multiple transactions at prices ranging from $18.34 to $18.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000034 · wk-form4_1741216805.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,899

F1 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan, as defined under the Company's Insider Trading Policy.

F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000035 · wk-form4_1741217056.xml · derivative · entry 3

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the restricted stock units will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4).

F5 · derivative.expiration_date: All shares of Axogen, Inc. common stock underlying the restricted stock units will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4).

SEC source: 0000805928-25-000035 · wk-form4_1741217056.xml · nonDerivative · entry 1

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on March 1, 2025.

SEC source: 0000805928-25-000028 · wk-form4_1741134151.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,301

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.